The Defense Ministry-run Israel Institute for Biological Research (IIBR) has inked a memorandum of understanding with NRx Pharmaceuticals to complete the clinical trials of its homegrown COVID-19 vaccine, according to a statement.
NRx Pharmaceuticals will push the vaccine, known as Brilife, to third-stage clinical trials, which will be conducted on tens of thousands of volunteers in Georgia, Ukraine and Israel, the statement says. The pharmaceutical company will then oversee its commercialization.
Defense Minister Benny Gantz visits a laboratory in the Israel Institute for Biological Research on October 25, 2020. (Defense Ministry)
Defense Minister Benny Gantz hails the agreement, calling it “excellent news.”
“I anticipate that with this agreement, we will be able to complete the development of the vaccine and enable Israel to produce vaccines independently, because as we have seen recently – the coronavirus is not going anywhere,” says Gantz.
“At the same time, the IIBR and the entire defense establishment will continue to take part in the national effort to counter the effects of this pandemic. I would like to thank the scientists of the institute, who never stop working to protect us – whether it be in the area of defense or health.”
The Israeli vaccine is still deep in the trial phase. In December, the Institute for Biological Research successfully completed the first stage of testing and started the second phase, which is ongoing.
Help us report truthfully on social media
As a multimedia journalist, my job is to take the quality, fact-based journalism produced by The Times of Israel newsroom and make it accessible across every platform — from Instagram posts to podcasts to short-form videos.
This is how many, especially young people, consume news these days. But misinformation is rampant on social media. Our team at ToI produces accurate, responsible short-form reporting on Israel and the Jewish world.
If you believe in the importance of factual social media journalism, please consider joining our reader support group, The Times of Israel Community. Your financial support is essential to sustain responsible multimedia reporting.
We’re really pleased that you’ve read X Times of Israel articles in the past month.
That’s why we started the Times of Israel - to provide discerning readers like you with must-read coverage of Israel and the Jewish world.
So now we have a request. Unlike other news outlets, we haven’t put up a paywall. But as the journalism we do is costly, we invite readers for whom The Times of Israel has become important to help support our work by joining The Times of Israel Community.
For as little as $6 a month you can help support our quality journalism while enjoying The Times of Israel AD-FREE, as well as accessing exclusive content available only to Times of Israel Community members.
Thank you, David Horovitz, Founding Editor of The Times of Israel
From the Liveblog of
Monday, July 12, 2021
Add ToI as a Preferred Source on Google
